| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEWS |
From the Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Address reprint requests to: Jodi A. Flaws, PhD, Department of Epidemiology and Preventive Medicine, University of Maryland Medical School, Howard Hall, Room 133B, 660 West Redwood St., Baltimore, MD 21201-1596; E-mail: jflaws{at}epi.umaryland.edu
OBJECTIVE: To assess whether recent epidemiologic evidence supports an association between use of estrogen replacement therapy or hormone replacement therapy and risk of breast cancer.
DATA SOURCES: The keywords "estrogen," "estrogen replacement therapy," or "hormone replacement therapy," and "breast cancer" or "breast neoplasm," were used to search for articles published from 1975–2000 in MEDLINE and Dialogweb. Only articles published in peer-reviewed journals and containing original data were included in this review.
METHODS: Unadjusted or age-adjusted risk estimates for breast cancer among ever users of estrogen therapy compared with never users were abstracted from published articles or calculated using the data provided in the published reports.
TABULATION, INTEGRATION, AND RESULTS: We found little consistency among studies that estimated the risk of breast cancer in hormone users compared with nonusers and in studies assessing the risk by duration of use. However, there was consistently a lower risk of death from breast cancer in hormone users compared with nonusers.
CONCLUSION: The evidence did not support the hypotheses that estrogen use increases the risk of breast cancer and that combined hormone therapy increases the risk more than estrogen only. Additional observational studies are unlikely to alter this conclusion. Although a small increase in breast cancer risk with hormone therapy or an increased risk with long duration of use (15 years or more) cannot be ruled out, the likelihood of this must be small, given the large number of studies conducted to date.
This article has been cited by other articles:
|
|
 |
|
  G. MASTORAKOS, E. GR. SAKKAS, A. M. XYDAKIS, and G. CREATSAS Pitfalls of the WHIs: Women's Health Initiative Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lyytinen, E. Pukkala, and O. Ylikorkala Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy Obstet. Gynecol., December 1, 2006; 108(6): 1354 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Stevenson and on behalf of the International Consensus Group on HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Hum. Reprod., July 1, 2006; 21(7): 1668 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pentti, R. Honkanen, M. T Tuppurainen, L. Sandini, H. Kroger, and S. Saarikoski Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study Eur. J. Endocrinol., January 1, 2006; 154(1): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Collins, J. M. Blake, and P. G. Crosignani Breast cancer risk with postmenopausal hormonal treatment Hum. Reprod. Update, November 1, 2005; 11(6): 545 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saitoh, M. Ohmichi, K. Takahashi, J. Kawagoe, T. Ohta, M. Doshida, T. Takahashi, H. Igarashi, A. Mori-Abe, B. Du, et al. Medroxyprogesterone Acetate Induces Cell Proliferation through Up-Regulation of Cyclin D1 Expression via Phosphatidylinositol 3-Kinase/Akt/Nuclear Factor-{kappa}B Cascade in Human Breast Cancer Cells Endocrinology, November 1, 2005; 146(11): 4917 - 4925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Pinheiro, M. D. Holmes, M. N. Pollak, R. L. Barbieri, and S. E. Hankinson Racial Differences in Premenopausal Endogenous Hormones Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2147 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Guttuso Jr, R. Kurlan, M. P. McDermott, and K. Kieburtz Gabapentin's Effects on Hot Flashes in Postmenopausal Women: A Randomized Controlled Trial Obstet. Gynecol., February 1, 2003; 101(2): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H MacLennan, B. Lawton, R. J Baber, M. Baum, and J M Dixon Hormone replacement therapy and the breast BMJ, April 13, 2002; 324(7342): 915 - 915. [Full Text]
|
|
|
|
 |
|
 L. Bogin and H. Degani Hormonal Regulation of VEGF in Orthotopic MCF7 Human Breast Cancer Cancer Res., April 1, 2002; 62(7): 1948 - 1951. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
